Loading...
OTCM
HCIL
Market cap123mUSD
Jul 10, Last price  
0.12USD
1Q
16.50%
Jan 2017
1,088.12%
Name

Heyu Biological Technology Corp

Chart & Performance

D1W1MN
OTCM:HCIL chart
P/E
P/S
43.21
EPS
Div Yield, %
Shrs. gr., 5y
-7.33%
Rev. gr., 5y
%
Revenues
3m
+7.14%
3,260,0005,043,000660,9879,221,000312,2458,569,0001,702,0001,082,0001,664,0006,578,0003,177,000188,21200163,680222,70196,47878,9532,676,0002,867,000
Net income
-472k
L+24.54%
-296,000-1,026,000876,228490,8654,817,00046,811-1,000,000-811,000-3,682,000-499,000-3,541,000-159,000-54,113-248,000-488,000-548,000-163,020-265,379-379,000-472,000
CFO
-7m
L
-241,057-364,546822,574-308,3224,429,5211,662,791-171,647-1,122,695-981,215-1,558,827-378,376-308,030-41,300-265,263-546,626-21,849-141,144-292,300750,521-7,337,639

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Heyu Biological Technology Corporation, alongside its subsidiaries, focuses on the research, development, and production of healthcare equipment. A key area of its present work involves developing the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber, a medical device intended for cancer treatment. This innovative equipment is designed to induce cold nuclear fusion via cosmic ray muons within a contained environment to combat the disease. The company, incorporated in 1987 and headquartered in Xiamen, People's Republic of China, was formerly known as Pacific WebWorks, Inc., before adopting its current name, Heyu Biological Technology Corporation, in June 2018.
IPO date
Nov 05, 1999
Employees
Domiciled in
CN
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT